VVP
ABBV icon

Venture Visionary Partners’s AbbVie ABBV Stock Holding History

Venture Visionary Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.74M Buy
38,688
+4,003
+12% +$861K 0.27% 96
2026
Q1 		$7.54M Buy
34,685
+1,230
+4% +$273K 0.25% 106
2025
Q4 		$7.75M Sell
33,455
-31
-0.1% -$7.06K 0.25% 100
2025
Q3 		$7.75M Sell
33,486
-2,284
-6% -$465K 0.27% 96
2025
Q2 		$6.64M Sell
35,770
-8,593
-19% -$1.6M 0.25% 99
2025
Q1 		$9.3M Sell
44,363
-2,322
-5% -$451K 0.39% 66
2024
Q4 		$8.3M Buy
46,685
+1,917
+4% +$352K 0.35% 73
2024
Q3 		$8.84M Sell
44,768
-276
-0.6% -$51.5K 0.38% 74
2024
Q2 		$7.73M Buy
45,044
+687
+2% +$114K 0.36% 77
2024
Q1 		$8.08M Sell
44,357
-540
-1% -$93.1K 0.38% 72
2023
Q4 		$6.96M Buy
44,897
+395
+0.9% +$57.6K 0.37% 77
2023
Q3 		$6.63M Sell
44,502
-479
-1% -$70.3K 0.4% 69
2023
Q2 		$6.06M Buy
44,981
+987
+2% +$145K 0.36% 77
2023
Q1 		$7.01M Buy
43,994
+924
+2% +$141K 0.44% 62
2022
Q4 		$6.96M Sell
43,070
-738
-2% -$113K 0.5% 50
2022
Q3 		$5.88M Buy
43,808
+1,366
+3% +$196K 0.48% 53
2022
Q2 		$6.5M Buy
42,442
+809
+2% +$124K 0.49% 49
2022
Q1 		$6.75M Sell
41,633
-25,232
-38% -$3.67M 0.45% 58
2021
Q4 		$9.09M Buy
66,865
+3,566
+6% +$421K 0.59% 43
2021
Q3 		$6.85M Buy
63,299
+4,054
+7% +$463K 0.49% 50
2021
Q2 		$6.68M Buy
59,245
+3,486
+6% +$393K 0.54% 40
2021
Q1 		$6.03M Buy
55,759
+21,814
+64% +$2.33M 0.5% 44
2020
Q4 		$3.64M Buy
33,945
+22,382
+194% +$2.15M 0.4% 54
2020
Q3 		$1.05M Buy
11,563
+1,888
+20% +$178K 0.26% 59
2020
Q2 		$949K Buy
9,675
+2,545
+36% +$224K 0.28% 53
2020
Q1 		$543K Buy
7,130
+3,351
+89% +$285K 0.2% 74
2019
Q4 		$334K Buy
+3,779
New +$314K 0.1% 121

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Venture Visionary Partners's ABBV Position: Q2 2026 in Review

Venture Visionary Partners increased its AbbVie (ABBV) stake by 12% in Q2 2026, buying an estimated $861K and bringing the position to 38,688 shares worth $9.74M. The position accounts for 0.27% of the portfolio, ranked #96.

Venture Visionary Partners first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Venture Visionary Partners held 38,688 shares of AbbVie worth $9.74M as of Q2 2026.
  • Venture Visionary Partners bought 4,003 AbbVie shares in Q2 2026, an estimated $861K.
  • AbbVie made up 0.27% of Venture Visionary Partners's portfolio in Q2 2026, its #96 holding.
  • Venture Visionary Partners first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Venture Visionary Partners's 13F filing for Q2 2026, filed 27 Jul 2026.